NovaBridge Biosciences (NBP) Receivables (2020 - 2022)

NovaBridge Biosciences (NBP) has reported Receivables for 3 consecutive years, with $1.2 million the latest figure, recorded in Q4 2022.

• Quarterly Receivables fell 81.35% year-over-year to $1.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.2 million (down 81.35% YoY) and the FY2022 annual result came in at $1.2 million, down 100.0% from the prior year.
• Receivables eased to $1.2 million in Q4 2022 per NBP's latest filing, from $37.9 million in the prior quarter.
• Over the last five years, Receivables for NBP reached as high as $42.2 million in Q4 2020 and fell as low as $1.2 million in Q4 2022.
• A 3-year average of $24.5 million and a median of $35.2 million in 2021 frame the typical range for Receivables.
• Annual changes were most pronounced in 2021 — Receivables tumbled 85.28% — and 2022, when it advanced 7.57%.
• Year by year, Receivables stood at $42.2 million in 2020, then slumped by 85.28% to $6.2 million in 2021, then tumbled by 81.35% to $1.2 million in 2022.
• According to Business Quant data, Receivables over the past three periods registered $1.2 million, $37.9 million, and $6.2 million for Q4 2022, Q2 2022, and Q4 2021 respectively.